KR20220066290A - Perk 억제 피롤로피리미딘 화합물 - Google Patents

Perk 억제 피롤로피리미딘 화합물 Download PDF

Info

Publication number
KR20220066290A
KR20220066290A KR1020227010197A KR20227010197A KR20220066290A KR 20220066290 A KR20220066290 A KR 20220066290A KR 1020227010197 A KR1020227010197 A KR 1020227010197A KR 20227010197 A KR20227010197 A KR 20227010197A KR 20220066290 A KR20220066290 A KR 20220066290A
Authority
KR
South Korea
Prior art keywords
alkyl
amino
pyrrolo
pyrimidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227010197A
Other languages
English (en)
Korean (ko)
Inventor
마크 제이. 멀비힐
안-후 리
매튜 데이비드 서먼
Original Assignee
히버셀, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히버셀, 인크. filed Critical 히버셀, 인크.
Publication of KR20220066290A publication Critical patent/KR20220066290A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227010197A 2019-08-29 2020-08-28 Perk 억제 피롤로피리미딘 화합물 Ceased KR20220066290A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
US62/893,528 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (1)

Publication Number Publication Date
KR20220066290A true KR20220066290A (ko) 2022-05-24

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227010197A Ceased KR20220066290A (ko) 2019-08-29 2020-08-28 Perk 억제 피롤로피리미딘 화합물

Country Status (12)

Country Link
US (1) US20220356186A1 (https=)
EP (1) EP4021908A1 (https=)
JP (1) JP2022546414A (https=)
KR (1) KR20220066290A (https=)
CN (1) CN114710956A (https=)
AU (1) AU2020336975A1 (https=)
BR (1) BR112022003584A2 (https=)
CA (1) CA3152508A1 (https=)
IL (1) IL290889A (https=)
MX (1) MX2022002446A (https=)
PH (1) PH12022550491A1 (https=)
WO (1) WO2021041975A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585606A (zh) 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
JP6493218B2 (ja) * 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
ES2965081T3 (es) * 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
RS65914B1 (sr) * 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja

Also Published As

Publication number Publication date
US20220356186A1 (en) 2022-11-10
IL290889A (en) 2022-04-01
CN114710956A (zh) 2022-07-05
PH12022550491A1 (en) 2023-02-06
EP4021908A1 (en) 2022-07-06
BR112022003584A2 (pt) 2022-05-24
MX2022002446A (es) 2022-06-02
JP2022546414A (ja) 2022-11-04
WO2021041975A1 (en) 2021-03-04
AU2020336975A1 (en) 2022-03-31
CA3152508A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
KR20220066290A (ko) Perk 억제 피롤로피리미딘 화합물
CN107573332B (zh) 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用
CN114945566A (zh) 作为钠通道调节剂的取代四氢呋喃
US12473296B2 (en) Perk inhibiting compounds
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
WO2021041976A1 (en) Perk inhibiting indolinyl compounds
US12331054B2 (en) Perk inhibiting imidazolopyrazine compounds
WO2016041489A1 (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
CN105646389A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
RU2720488C2 (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
CN110156674A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CN105523955A (zh) 化合物及其在制备药物中的用途
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
TW202341987A (zh) 一種Polθ抑制劑
WO2022063297A1 (zh) 喹唑啉衍生物及其制备方法和用途
CN106986859B (zh) 吲哚衍生物及其用途
WO2022002100A1 (zh) 新型苯并咪唑化合物
EP4041732B1 (en) Iso-citrate dehydrogenase (idh) inhibitor
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
KR20260022307A (ko) Trek(twik 관련 k+ 채널) 채널 기능의 억제제
TW202540096A (zh) 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途
HK40119524A (zh) 三环类化合物及其用途
CN106674207A (zh) 取代的芳基杂芳基化合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601